China

Showing 1–16 of 19 results

China NMPA (Order No. 28): Administrative Measures for Drugs Registration
$350.00 Add to cart
China NMPA (Order No.4): Administrative Measures for Drugs Importation
$350.00 Add to cart
China NMPA (Order No.48,2020) : CDE Communication During Drug R&D and Technical Evaluation,
$200.00 Add to cart
China NMPA: Approval of Active Pharmaceutical Ingredients (API), Pharmaceutical Excipients and Pharmaceutical Packaging Materials for Drug Products No.146, November 30, 2017
$100.00 Add to cart
China’s NMPA Decree No. 1 – Annex 3: Guideline on Medical Device Adverse Event Monitoring Scope (Draft)
$200.00 Add to cart
China’s NMPA Decree No. 1 – Annex 7: Guideline on Focus Points when Monitoring Medical Device Adverse Events (Draft)
$150.00 Add to cart
China’s NMPA Decree No. 131: Announcement on Using Chinese Name for Registrant or File Submitter of Imported Medical Devices
$100.00 Add to cart
China’s NMPA Decree No. 6: Guideline on the Design of Clinical Trials for Medical Devices
$150.00 Add to cart
China’s NMPA Decree No. 6: Regulation on Instructions for Use and Labels of Medical Devices
$200.00 Add to cart
China’s NMPA DECREE NO. 7 : Measures for Supervision and Administration of Medical Device Production
$50.00 Add to cart
China’s NMPA Decree No. 83: Innovative Medical Device Special Approval Procedure
$200.00 Add to cart
China’s NMPA Guideline No. 101: Registration of Rare Disease Control Medical Devices
$100.00 Add to cart
China’s NMPA Order No. 56 of 2019: Improving Related Issues Concerning Drug Evaluation, Approval and Supervision (DMF for API, Pharmaceutical Packaging Materials and Excipient
$100.00 Add to cart
China’s NMPA” Guideline for Technical Review of Medical Device Software Registration
$200.00 Add to cart
China’s NMPA: Announcement on Record Filling of Medical Device Master Files
$50.00 Add to cart
China’s NMPA: Guideline for Clinical Trials of In Vitro Diagnostic Reagents (Draft)
$150.00 Add to cart

North America

Latin AMerica

Europe

Australia

Asia

China NMPA (Order No. 28): Administrative Measures for Drugs Registration

China NMPA (Order No.4): Administrative Measures for Drugs Importation

China NMPA (Order No.48,2020) : CDE Communication During Drug R&D and Technical Evaluation,

China NMPA: Approval of Active Pharmaceutical Ingredients (API), Pharmaceutical Excipients and Pharmaceutical Packaging Materials for Drug Products No.146, November 30, 2017

China’s NMPA Decree No. 1 – Annex 3: Guideline on Medical Device Adverse Event Monitoring Scope (Draft)

China’s NMPA Decree No. 1 – Annex 7: Guideline on Focus Points when Monitoring Medical Device Adverse Events (Draft)

China’s NMPA Decree No. 131: Announcement on Using Chinese Name for Registrant or File Submitter of Imported Medical Devices

China’s NMPA Decree No. 6: Guideline on the Design of Clinical Trials for Medical Devices

China’s NMPA Decree No. 6: Regulation on Instructions for Use and Labels of Medical Devices

China’s NMPA DECREE NO. 7 : Measures for Supervision and Administration of Medical Device Production

China’s NMPA Decree No. 83: Innovative Medical Device Special Approval Procedure

China’s NMPA Guideline No. 101: Registration of Rare Disease Control Medical Devices

China’s NMPA Order No. 56 of 2019: Improving Related Issues Concerning Drug Evaluation, Approval and Supervision (DMF for API, Pharmaceutical Packaging Materials and Excipient

China’s NMPA” Guideline for Technical Review of Medical Device Software Registration

China’s NMPA: Announcement on Record Filling of Medical Device Master Files

China’s NMPA: Guideline for Clinical Trials of In Vitro Diagnostic Reagents (Draft)

ABOUT GRP GROUP

Useful Links

GRP Headquarters (USA)

22 Boston Warf Road, Boston, MA, 02210, USA

Tel : (+1 ) 781 - 672 -4200

Info@globalregulatorypartners.com

GRP Group Offices

Follow Us on Social Media